KRX Growth Leaders With High Insider Stakes In South Korea

In the past year, South Korea's market has seen a modest increase of 4.3%, despite a recent dip of 2.1% over the last seven days. High insider ownership in growth companies can be particularly appealing in such an environment, as it often signals strong confidence from those who know the company best.

Top 10 Growth Companies With High Insider Ownership In South Korea

Name	Insider Ownership	Earnings Growth
ALTEOGEN (KOSDAQ:A196170)	26.6%	73.1%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	36.4%
Global Tax Free (KOSDAQ:A204620)	18.1%	72.4%
Seojin SystemLtd (KOSDAQ:A178320)	29.8%	58.7%
Park Systems (KOSDAQ:A140860)	33%	36.3%
Vuno (KOSDAQ:A338220)	19.5%	105%
UTI (KOSDAQ:A179900)	33.1%	122.7%
INTEKPLUS (KOSDAQ:A064290)	16.3%	77.4%
HANA Micron (KOSDAQ:A067310)	20%	99.6%
Techwing (KOSDAQ:A089030)	18.7%	77.8%

Click here to see the full list of 79 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Medy-Tox (KOSDAQ:A086900)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Medy-Tox Inc. is a biopharmaceutical company based in South Korea, with a market capitalization of approximately ₩1.18 billion.

Operations: The company generates its revenue from biopharmaceutical operations in South Korea.

Insider Ownership: 19.8%

Medy-Tox, a South Korean biopharmaceutical company, exhibits high insider ownership but faces challenges with a highly volatile share price and recent significant financial setbacks, reporting a net loss of KRW 1.47 billion in Q1 2024. Despite these difficulties, the stock trades at 42% below its estimated fair value and shows promising growth forecasts with earnings expected to increase significantly over the next three years. However, its revenue growth is projected to be moderate and profit margins have declined from the previous year.

• Click here and access our complete growth analysis report to understand the dynamics of Medy-Tox.
• Insights from our recent valuation report point to the potential undervaluation of Medy-Tox shares in the market.

Seegene (KOSDAQ:A096530)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Seegene, Inc., a global company, specializes in manufacturing and selling molecular diagnostics products with a market capitalization of approximately ₩995.86 billion.

Operations: The company generates revenue primarily from its diagnostic kits and equipment, totaling approximately ₩367.27 billion.

Insider Ownership: 35.7%

Seegene, a South Korean company, is poised for profitability within three years, with earnings expected to grow significantly at 129.15% annually. Although its revenue growth of 13.1% per year is below the high-growth benchmark of 20%, it still outpaces the broader Korean market's average of 10.6%. Recent financials reveal a shift from net income to a loss in Q1 2024, alongside an extended buyback plan indicating potential confidence by management despite current challenges.

• Navigate through the intricacies of Seegene with our comprehensive analyst estimates report here.
• The valuation report we've compiled suggests that Seegene's current price could be quite moderate.

Devsisters (KOSDAQ:A194480)

Simply Wall St Growth Rating: ★★★★★★

Overview: Devsisters Corporation specializes in developing mobile games both in South Korea and internationally, with a market capitalization of approximately ₩563.53 billion.

Operations: The company generates revenue from the development of mobile games across domestic and international markets.

Insider Ownership: 26.8%

Devsisters, a South Korean growth company with high insider ownership, is trading at 62.6% below its estimated fair value, presenting a potential opportunity. The company's revenue is expected to grow by 24.1% annually, outperforming the Korean market's average of 10.6%. Earnings are projected to increase by 63.52% per year, and Devsisters is forecasted to become profitable within the next three years. However, investors should note the stock's high volatility over the past three months.

• Get an in-depth perspective on Devsisters' performance by reading our analyst estimates report here.
• In light of our recent valuation report, it seems possible that Devsisters is trading beyond its estimated value.

Turning Ideas Into Actions

• Discover the full array of 79 Fast Growing KRX Companies With High Insider Ownership right here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com